ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AUPH Aurinia Pharmaceuticals Inc

5.19
0.02 (0.39%)
After Hours
Last Updated: 22:26:49
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aurinia Pharmaceuticals Inc NASDAQ:AUPH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.02 0.39% 5.19 5.12 5.19 5.545 5.09 5.34 1,696,503 22:26:49

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

04/06/2019 9:05pm

Business Wire


Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Aurinia Pharmaceuticals Charts.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences:

  • Jefferies Healthcare Conference on Friday, June 7, 2019 at 9:30am PT (12:30pm ET) in New York, NY; and
  • Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 5:35am (8:35am ET) in New York, NY.

All presentations will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of each presentation will also be archived on the Company website following the event.

About Aurinia

Aurinia Pharmaceuticals Inc. is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations impacted by serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and dry eye syndrome (DES). The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

Company Contact:Glenn Schulman, PharmD, MPHCorporate Communicationsgschulman@auriniapharma.com

1 Year Aurinia Pharmaceuticals Chart

1 Year Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock